For your skin
A potent dark-spot fader long favored by dermatologists. Pairs strongly with niacinamide for stubborn discoloration without the irritation of hydroquinone.
Want the science? Keep reading ↓Mechanism of action
Resorcinol derivative that competitively inhibits tyrosinase and activates the Nrf2 antioxidant response, addressing both melanogenesis and pigment-driving oxidative stress.
Why we tier this moderate
5 cited papers across 3 countries. The mechanism is well-described and there's at least one controlled trial in the literature, but we tier this Moderate rather than Strong to stay honest about how many specific papers we cite directly.
Cited research
Wu A, Gabriel V, Burney W, Chambers C, Pan A, Sivamani RK, Prospective, randomized, double-blind clinical study of split-body comparison of topical hydroquinone and hexylresorcinol for skin pigment appearance, Archives of Dermatological Research 2023;315(7):2095-2099 — split-body RCT, 1% hexylresorcinol equivalent to 2% hydroquinone in pigmentation reduction at 4 and 12 weeks
Shariff R et al., Superior even skin tone and anti-ageing benefit of a combination of 4-hexylresorcinol and niacinamide, International Journal of Cosmetic Science 2022;44(1):103-117
Draelos ZD, Diaz I, Cohen A, Mao J, Boyd T, A novel skin brightening topical technology, Journal of Cosmetic Dermatology 2020;19(12):3280-3285 — 12-week clinical trial (n=42) of hexylresorcinol + silymarin + vitamins C/E showed 45% improvement in brightening and improvements in evenness and fine lines
Won YK et al., Clinical efficacy and safety of 4-hexyl-1,3-phenylenediol for improving skin hyperpigmentation, Archives of Dermatological Research 2014;306(5):455-465 — 12-week topical 4-hexylresorcinol RCT reduced skin hyperpigmentation
Makino ET, Mehta RC, Banga A, Jain P, Sigler ML, Sonti S, Evaluation of a hydroquinone-free skin brightening product using in vitro inhibition of melanogenesis and clinical reduction of ultraviolet-induced hyperpigmentation, Journal of Drugs in Dermatology 2013;12(3):s16-20
Sources: 10 clinical journals and regulatory databases across the US, EU, Korea, Japan, and China. Every entry points to a specific document. See methodology for the full list and what each outcome label means.